Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Chemotherapy for metastatic castrate-sensitive prostate cancer

Prostate Cancer and Prostatic Diseases volume 19, pages 139–144 (2016)Cite this article

Subjects

Abstract

Background:

The role of docetaxel chemotherapy in combination with androgen deprivation therapy for metastatic castrate-sensitive prostate cancer is emerging.

Methods:

We reviewed the results from the pivotal randomized phase III trials in this area: GETUG15, CHAARTED and STAMPEDE.

Results:

All three studies demonstrated a benefit in progression-free survival with the use of docetaxel. However, two of the studies demonstrated a clinically meaningful overall survival benefit (CHAARTED and STAMPEDE), whereas the GETUG15 study did not demonstrate a major benefit.

Conclusions:

Docetaxel is an important option to consider for men who are fit for chemotherapy with newly diagnosed metastatic prostate cancer commencing androgen deprivation therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.

    Article  CAS  PubMed  Google Scholar 

  2. Huggins C, Hodges CV . Studies in prostate cancer. 1. The effect of castration of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.

    CAS  Google Scholar 

  3. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818–823.

    Article  CAS  PubMed  Google Scholar 

  4. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012; 188: 1164–1169.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl J Med 2015; 373: 737–746.

    Article  CAS  PubMed  Google Scholar 

  6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011; 364: 1995–2005.

    Article  CAS  PubMed  Google Scholar 

  7. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154.

    Article  CAS  PubMed  Google Scholar 

  8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; 363: 411–422.

    Article  CAS  PubMed  Google Scholar 

  9. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New Engl J Med 2013; 369: 213–223.

    Article  CAS  PubMed  Google Scholar 

  10. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187–1197.

    Article  CAS  PubMed  Google Scholar 

  11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502–1512.

    Article  CAS  PubMed  Google Scholar 

  12. Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.

    Article  PubMed  Google Scholar 

  13. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT . Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003; 98: 1169–1178.

    Article  PubMed  Google Scholar 

  14. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P . Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006; 24: 396–402.

    Article  PubMed  Google Scholar 

  15. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092.

    Article  PubMed  Google Scholar 

  16. Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A et al. The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004; 351: 1513–1520.

    Article  CAS  PubMed  Google Scholar 

  18. Zielinski RR, Azad AA, Chi KN, Tyldesely S . Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. Can Urol Assoc J 2014; 8: E520–E523.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943–2947.

    Article  CAS  PubMed  Google Scholar 

  20. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur Cancer 2013; 49: 3821–3830.

    Article  CAS  Google Scholar 

  21. Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES . Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 2014; 74: 1278–1285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005; 11: 4905–4911.

    Article  CAS  PubMed  Google Scholar 

  23. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006; 12: 169–174.

    Article  CAS  PubMed  Google Scholar 

  24. de Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA et al. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 1999; 162: 1658–1664.

    Article  CAS  PubMed  Google Scholar 

  25. Janknegt RA, Boon TA, van de Beek C, Grob P . Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997; 49: 411–420.

    Article  CAS  PubMed  Google Scholar 

  26. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26: 5936–5942.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 2004; 11: 103–109.

    Article  CAS  PubMed  Google Scholar 

  28. Pummer K, Lehnert M, Stettner H, Hubmer G . Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32: 81–85.

    CAS  PubMed  Google Scholar 

  29. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J . Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000; 86: 675–680.

    Article  CAS  PubMed  Google Scholar 

  30. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149–158.

    Article  CAS  PubMed  Google Scholar 

  31. James ND SM, Mason MD, Clarke NW, Dearnaley DP, Spears MR, Millman R et al. STAMPEDE Investigators;. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33: abstr 5001.

    Article  Google Scholar 

  32. Gravis GB, JolyF, Oudard S, Albiges L, Priou F, Latorzeff I et al. Androgen deprivation therapy(ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015; 33: abstract 140.

    Article  Google Scholar 

  33. Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10: 39.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Glass TR, Tangen CM, Crawford ED, Thompson I . Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164–169.

    Article  CAS  PubMed  Google Scholar 

  35. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 1989; 321: 419–424.

    Article  CAS  PubMed  Google Scholar 

  36. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 1998; 339: 1036–1042.

    Article  CAS  PubMed  Google Scholar 

  37. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G et al. Intermittent versus continuous androgen deprivation in prostate cancer. New Engl J Med 2013; 368: 1314–1325.

    Article  CAS  PubMed  Google Scholar 

  38. Tait C, Moore D, Hodgson C, Brown M, Morris T, Growcott J et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114: E70–E73.

    Article  CAS  PubMed  Google Scholar 

  39. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26: 1589–1604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Vale CRL, Tierney JF, Albiges L, Clarke NW, Fisher DJ, Fizazi K et al. What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses. Eur J Cancer 2015; 51: 20LBA.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University College London Hospital, London, UK

    R E Miller

  2. Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA

    C J Sweeney

Authors
  1. R E Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C J Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C J Sweeney.

Ethics declarations

Competing interests

CJS has consultancy with honoraria for Astellas, BIND therapeutics, Sanofi, Janssen, Genentech and Bayer. The remaining author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miller, R., Sweeney, C. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis 19, 139–144 (2016). https://doi.org/10.1038/pcan.2016.10

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2016.10

This article is cited by

Search

Advanced search

Quick links